Morningstar

Eclipsebio Acquires Terrain Bio to Expand Its End-to-End AI Platform for the Design, Manufacturing, and Validation of RNA Therapeutics

Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in sequencing-based analytics for RNA therapeutics, today announced the acquisition of Terrain Bio, a techbio company specializing in AI/ML RNA ...
Business Wire

PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...
Euronews

Experts warn open access bio-data could help AI design dangerous pathogens

More than 100 researchers call for safeguards on high-risk biological datasets to prevent AI misuse, which could create deadly pathogens. Artificial intelligence (AI) models for biology rely heavily ...
PharmiWeb

RoukenBio and AVS Bio Announce Strategic Partnership to Integrate Design-Focused Antibody Discovery and Optimisation with Mechanism-Driven Functional Characterisation

Creation of an end-to-end antibody engine: rapid discovery paired with physiologically relevant translational assays to confirm MoA early and de-risk IND readiness. Motherwell, Scotland, [17] February ...
Forbes

From Silicon To Water: The Liquid, Bio-Inspired Future Of Data Centers

For many years, the landscape of data center innovation has been dominated by solid-state electronics. The relentless pursuit of faster chips, denser racks and larger facilities has been the mantra ...